Clinical trials: Essential Hypertension
- Condition Essential Hypertension
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Hypertension
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
The purpose of this study is to evaluate in a randomized, double-blind fashion, the long-term safety, tolerability and efficacy profile of aliskiren compared to the active comparator enalapril in children, 6 - 17 years old with…
- Trial name
- NCT01151410
- Testing
- Aliskiren, Enalapril
- Where
- 36 sites in United States, Guatemala and 5 more
- Volunteers
- 208 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Post Marketing Surveillance (PMS) Study to Assess Safety and Efficacy of Micardis in Patients With Essential Hypertension
The objective of this PMS study was to monitor and assess the safety of Micardis tablets in patients with hypertension over a period of 6 years
- Trial name
- NCT02245464
- Testing
- Telmisartan
- Volunteers
- 13,066 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
This double-blind 8 week study will evaluate dose response, efficacy (blood pressure lowering effect) and safety of aliskiren in children 6 - 17 years old with hypertension at low, mid and high weight-based doses.
- Trial name
- NCT01150357
- Testing
- Aliskiren (6.25/12.5/25 mg), Aliskiren (37.5/75/150 mg), Aliskiren (150/300/600 mg)
- Where
- 48 sites in United States, Belgium and 7 more
- Volunteers
- 267 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension
Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide
The CoCa study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e.
- Trial name
- CoCa (NCT00608153)
- Volunteers
- 1,773 people
- Sponsor
- AstraZeneca
Essential Hypertension, Left Ventricular Hypertrophy
Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH
The CandLE study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e.
- Trial name
- CandLE (NCT00607633)
- Volunteers
- 686 people
- Sponsor
- AstraZeneca
Hypertension
A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)
The purpose of this study is to test the safety and effectiveness of Losartan as compared to Losartan/HCTZ in pediatric patients (6 to 17 years) with high blood pressure.
- Trial name
- NCT00447603
- Testing
- hydrochlorothiazide (+) losartan potassium, losartan potassium
- Volunteers
- 40 people
- Sponsor
- Organon and Co
Hypertension
RIAT Registry: Reason for Not Intensifying Antihypertensive Treatment
To support physicians in their active management of hypertensive patients. By targeting specific systolic and diastolic blood pressure (BP) figures physicians will closely monitor the BP values and as such will have an…
- Trial name
- RIAT (NCT00258921)
- Volunteers
- 31,870 people
- Sponsor
- Sanofi
Essential Hypertension
A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension
The purpose of this study is to assess the long-term safety, tolerability and efficacy of LCZ696.
- Trial name
- NCT01256411
- Testing
- LCZ696, Amlodipine, Hydrochlorothiazide (HCTZ)
- Where
- 33 sites in China, Japan and 3 more
- Volunteers
- 341 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Evolution of Pulse Pressure Following Initiation of Antihypertensive Therapy in Patients With Essential Arterial Hypertension
The main purpose of this prospective, multicentre, french observational study is to analyse the evolution of pulse pressure (PP) and to identify its prognostic factors in hypertensive patients three months after initiation of a…
- Trial name
- NCT02202525
- Testing
- Micardis®, Other hypertensives
- Volunteers
- 2,148 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension
Using Losartan as a comparator, to evaluate the efficacy and safety of telmisartan in the treatment of the mild to moderate primary hypertension patients in China
- Trial name
- NCT02269176
- Testing
- Low dose of telmisartan, High dose of telmisartan, Low dose of losartan
- Volunteers
- 330 people
- Sponsor
- Boehringer Ingelheim
Hypertension
An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension
The purpose of the study is to evaluate the efficacy and safety of the study drug relative to an active comparator losartan which is in the same class of drug and is approved for use in the pediatric population aged 6 years and…
- Trial name
- NCT02235909
- Testing
- Azilsartan Medoxomil Low-dose, Losartan, Azilsartan Medoxomil Medium-dose (20 mg)
- Where
- 69 sites in United States, Argentina and 10 more
- Volunteers
- 377 people
- Sponsor
- Arbor Pharmaceuticals, Inc.
Essential Hypertension
A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents
This study was an randomized, double-Blind, placebo-controlled, multicenter Phase II/III study.
- Trial name
- NCT06863987
- Testing
- Valsartan Oral Solution
- Where
- China
- Volunteers
- 342 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD